Company News, Patents

Dermala Earns Patent for Microbiome-Derived Postbiotics for Acne Care

US Patent No. 11,040,046 covers compositions and methods for treating acne vulgaris.

Author Image

By: Christine Esposito

Editor-in-Chief

Consumer dermatology company Dermala, Inc. has been granted US Patent No. 11,040,046 “Compositions and Methods for Treating Acne Vulgaris,” which covers using the human microbiome to treat and prevent acne.    Dermala’s patented technology uses novel, human microbiome-derived postbiotics, metabolites derived from beneficial bacteria in the human microbiome, that inhibit acne-causing C. acnes bacteria, including antibiotic-resistant clinical isolates from individuals with treatment-resistant acne...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters